Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

In-Jin Jang

Showing results (61-70 of 292) with videos related to

Pageof 30
Sort By:
Drug Design, Development and Therapy|February 29, 2020
Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy VolunteersDeok Yong Yoon, Sang-In Park, Jin-A Jung, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2020
Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicitiesJun Gi Hwang, Inseung Jeon, Sun Ae Park, et al.
British Journal of Clinical Pharmacology|October 13, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjectsYasuhiro Tsuda, Christine Grimaldi, Fenglei Huang, et al.
Translational and Clinical Pharmacology|October 8, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platformByungwook Kim, Deok Yong Yoon, SeungHwan Lee, et al.
British Journal of Clinical Pharmacology|December 10, 2022
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adultsSae Im Jeong, Yun Kim, Jae Jin Nah, et al.
British Journal of Clinical Pharmacology|April 23, 2002
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19Joo-Youn Cho, Kyung-Sang Yu, In-Jin Jang, et al.
Clinical Pharmacology and Therapeutics|September 7, 2017
Identification of ω- or (ω-1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A ActivityBora Kim, Jieon Lee, Kwang-Hee Shin, et al.
Clinical Therapeutics|November 25, 2010
Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteersTae-Eun Kim, Kyu-Pyo Kim, Bo-Hyung Kim, et al.
Clinical and Translational Science|October 20, 2021
Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non-JapaneseEunsol Yang, Jung Sunwoo, Ki Young Huh, et al.
Drug Design, Development and Therapy|July 8, 2024
Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy SubjectsHyunwook Ryu, Hyun Chul Kim, Inseung Jeon, et al.
Pageof 30

Showing results (61-70 of 292) with videos related to

Sort By:
Pageof 30
Drug Design, Development and Therapy|February 29, 2020
Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy VolunteersDeok Yong Yoon, Sang-In Park, Jin-A Jung, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2020
Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicitiesJun Gi Hwang, Inseung Jeon, Sun Ae Park, et al.
British Journal of Clinical Pharmacology|October 13, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjectsYasuhiro Tsuda, Christine Grimaldi, Fenglei Huang, et al.
Translational and Clinical Pharmacology|October 8, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platformByungwook Kim, Deok Yong Yoon, SeungHwan Lee, et al.
British Journal of Clinical Pharmacology|December 10, 2022
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adultsSae Im Jeong, Yun Kim, Jae Jin Nah, et al.
British Journal of Clinical Pharmacology|April 23, 2002
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19Joo-Youn Cho, Kyung-Sang Yu, In-Jin Jang, et al.
Clinical Pharmacology and Therapeutics|September 7, 2017
Identification of ω- or (ω-1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A ActivityBora Kim, Jieon Lee, Kwang-Hee Shin, et al.
Clinical Therapeutics|November 25, 2010
Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteersTae-Eun Kim, Kyu-Pyo Kim, Bo-Hyung Kim, et al.
Clinical and Translational Science|October 20, 2021
Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non-JapaneseEunsol Yang, Jung Sunwoo, Ki Young Huh, et al.
Drug Design, Development and Therapy|July 8, 2024
Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy SubjectsHyunwook Ryu, Hyun Chul Kim, Inseung Jeon, et al.
Pageof 30